ERT, a leading provider of ePRO, centralized ECG and other services to the biopharmaceutical, medical device and related industries, has won a prestigious award at the 2009 European Outsourcing Awards (EOA) ceremony, held in Madrid on 14 October. ERT were honoured with the award for Best New Product for its innovative electronic Patient Reported Outcomes (ePRO) based suicidality monitoring solution, affirming its market leading position within the ePRO community.
The EOA Awards are designed to recognize new and significant developments in contract services and reward successful companies for their outstanding contributions throughout the year. ERT was crowned winner of the Best New Product category over four strong competitors. The panel of EOA judges was impressed with the innovation shown by ERT in the development of its suicidality monitoring solution. ERT's solution overcomes many of the challenges associated with monitoring suicidal tendencies during clinical trials and significantly improves patient safety throughout the clinical trial lifecycle.
Recent FDA comment has guided the clinical trials industry to require that prospective suicidality tendencies should be monitored in every Phase II - IV clinical study, in every protocol and at every visit across all therapeutic areas. Suicidality monitoring is just one solution from ERT's ePRO product portfolio and is used to improve patient safety during clinical trials. Uniquely the solution provides clinicians with a response system that assures swift reaction to suicide concerns. Certain patient-reported answers trigger alerts to multiple parties including sites, clinical research associates, contract research organizations and is monitored by a pair of call centers that maintain contact with the patient until the responsible investigator is reached and the patient is successfully contacted. This process is initiated before the patient is even finished with the questionnaire. More in-depth clinical follow-up and evaluation are ensured, resulting in maximum patient safety.
Michael McKelvey, President and CEO of ERT, said: "We are delighted to receive this award which recognizes the considerable efforts of our talented team and the exceptional caliber of the nominees across all categories. ERT understands the scientific and regulatory issues associated with clinical trials, and this award reflects our desire to be a collaborative partner that is both dependable and flexible."
ERT was also awarded a runner-up prize in the best eBusiness category for My Study Portal - an easy-to-use web-based portal which provides users with secure 24/7 access to a centralized environment to view and manage vital data from anywhere in the world. My Study Portal is an industry-leading, 21 CFR Part 11-compliant, clinical trial portal used by sponsors to drive smarter decision making based on real-time data reporting.
For further press information, please contact Fiona Robinson, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA, United Kingdom. P: +44 1477 539539, F: +44 1477 539540, E ert[.]scottpr.co.uk.
Based in Philadelphia, PA, ERT (eResearchTechnology, Inc.) is a leading provider of centralized ECG, ePRO, and other services to the biopharmaceutical, medical device, and related industries. ERT products and services (ert.com) are enabled by EXPERT, the Company's robust, secure, and validated clinical research workflow-processing system that powers centralized electronic data collection, data management, and information exchange.
Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties, which could cause actual results to differ materially from those expressed or implied from such statements. These risks and uncertainties include, without limitation, the Company's ability to obtain new contracts, variability in size, scope and duration of projects, integration of acquisitions, competitive factors, technological development, market demand, and other factors described in the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.